BioAge reports Q3 2026 results, updates timelines for BGE-102 trials
BioAge dosed its first diabetic macular edema patient in September, completed enrollment in its cardiovascular trial, and said cash runs through 2029.
SEC filing
3 stories
BioAge dosed its first diabetic macular edema patient in September, completed enrollment in its cardiovascular trial, and said cash runs through 2029.
SEC filing
The trial, called QUELL-DME, will test the oral NLRP3 inhibitor alone and alongside anti-VEGF therapy in about 180 participants, with topline data expected in the second half of 2027.
SEC filing